FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2325-2334 December 1, 2005 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Kim, J. Y. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The one-year survival rate of adults and children with the acquired immunodeficiency syndrome (AIDS), without antiretroviral therapy, has been about 30 percent in Haiti. Antiretroviral therapy has recently become available in Haiti and in other developing countries. Data on the efficacy of antiretroviral therapy in developing countries are limited. High rates of coinfection with tropical diseases and tuberculosis, along with malnutrition and limited laboratory monitoring of therapy, may decrease the efficacy of antiretroviral therapy in these countries.

Methods We studied the efficacy of antiretroviral therapy in the first 1004 consecutive patients with AIDS and without previous antiretroviral therapy who were treated beginning in March 2003 in Port-au-Prince, Haiti.

Results During a 14-month period, three-drug antiretroviral therapy was initiated in 1004 patients, including 94 children under 13 years of age. At enrollment, the median CD4 T-cell count in adults and adolescents was 131 per cubic millimeter (interquartile range, 55 to 211 per cubic millimeter); in children, a median of 13 percent of T cells were CD4-positive (interquartile range, 8 to 20 percent). According to a Kaplan–Meier survival analysis, 87 percent of adults and adolescents and 98 percent of children were alive one year after beginning treatment. In a subgroup of 100 adult and adolescent patients who were followed for 48 to 56 weeks, 76 patients had fewer than 400 copies of human immunodeficiency virus RNA per milliliter. In adults and adolescents, the median increase in the CD4 T-cell count from baseline to 12 months was 163 per cubic millimeter (interquartile range, 77 to 251 per cubic millimeter). In children, the median percentage of CD4 T cells rose from 13 percent at baseline to 26 percent (interquartile range, 22 to 36 percent) at 12 months. Treatment-limiting toxic effects occurred in 102 of the 910 adults and adolescents (11 percent) and 5 of the 94 children (5 percent).

Conclusions This report documents the feasibility of effective antiretroviral therapy in a large number of patients in an impoverished country. Overall, the outcomes are similar to those in the United States. These results provide evidence in support of international efforts to make antiretroviral therapy available to patients with AIDS in developing countries.

Source Information

From the Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, Haiti (P.S., P.L., M.C., F.N., G. Bonhomme, G. Bois, E.G., S.K.-P., J.W.P.); the Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York (M.C., E.G., R.G., W.D.J., J.W.P., D.W.F.); and the Division of Pediatric Infectious Diseases, Vanderbilt University, Nashville (P.W.).

Address reprint requests to Dr. Fitzgerald at the Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, Room A-421, 1300 York Ave., New York, NY 10021 or at dfitzgerald{at}gheskio.org.

Full Text of this Article

This article has been cited by other articles:

• Labbett, W., Garcia-Diaz, A., Fox, Z., Clewley, G. S., Fernandez, T., Johnson, M., Geretti, A. M. (2009). Comparative Evaluation of the ExaVir Load Version 3 Reverse Transcriptase Assay for Measurement of Human Immunodeficiency Virus Type 1 Plasma Load. J. Clin. Microbiol. 47: 3266-3270 [Abstract] [Full Text]  
• Leger, P., Charles, M., Severe, P., Riviere, C., Pape, J. W., Fitzgerald, D. W. (2009). 5-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti. NEJM 361: 828-829 [Full Text]  
• Zhang, F., Dou, Z., Ma, Y., Zhao, Y., Liu, Z., Bulterys, M., Chen, R. Y. (2009). Five-Year Outcomes of the China National Free Antiretroviral Treatment Program. ANN INTERN MED 151: 241-251 [Abstract] [Full Text]  
• Dillingham, R. A., Pinkerton, R., Leger, P., Severe, P., Guerrant, R. L., Pape, J. W., Fitzgerald, D. W. (2009). High Early Mortality in Patients with Chronic Acquired Immunodeficiency Syndrome Diarrhea Initiating Antiretroviral Therapy in Haiti: A Case-Control Study. Am J Trop Med Hyg 80: 1060-1064 [Abstract] [Full Text]  
• Uzochukwu, B S C, Onwujekwe, O E, Onoka, A C, Okoli, C, Uguru, N P, Chukwuogo, O I (2009). Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan 24: 189-196 [Abstract] [Full Text]  
• Bajunirwe, F., Arts, E. J., Tisch, D. J., King, C. H., Debanne, S. M., Sethi, A. K. (2009). Adherence and Treatment Response Among HIV-1-Infected Adults Receiving Antiretroviral Therapy in a Rural Government Hospital in Southwestern Uganda. J Int Assoc Physicians AIDS Care (Chic Ill) 8: 139-147 [Abstract]  
• Stover, J, Johnson, P, Zaba, B, Zwahlen, M, Dabis, F, Ekpini, R E (2008). The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex. Transm. Infect. 84: i24-i30 [Abstract] [Full Text]  
• Fairall, L. R., Bachmann, M. O., Louwagie, G. M. C., van Vuuren, C., Chikobvu, P., Steyn, D., Staniland, G. H., Timmerman, V., Msimanga, M., Seebregts, C. J., Boulle, A., Nhiwatiwa, R., Bateman, E. D., Zwarenstein, M. F., Chapman, R. D. (2008). Effectiveness of Antiretroviral Treatment in a South African Program: A Cohort Study. Arch Intern Med 168: 86-93 [Abstract] [Full Text]  
• McGowan, C. C, Cahn, P., Gotuzzo, E., Padgett, D., Pape, J. W, Wolff, M., Schechter, M., Masys, D. R (2007). Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 36: 969-976 [Full Text]  
• Kim, A. A., Wanjiku, L., Macharia, D. K., Wangai, M., Isavwa, A., Abdi, H., Marston, B. J., Ilako, F., Kjaer, M., Chebet, K., De Cock, K. M., Weidle, P. J. (2007). Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003-2005. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 206-209 [Abstract]  
• Rapaka, R. R., Goetzman, E. S., Zheng, M., Vockley, J., McKinley, L., Kolls, J. K., Steele, C. (2007). Enhanced Defense against Pneumocystis carinii Mediated by a Novel Dectin-1 Receptor Fc Fusion Protein. J. Immunol. 178: 3702-3712 [Abstract] [Full Text]  
• Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., Rachlis, B., Wu, P., Cooper, C., Thabane, L., Wilson, K., Guyatt, G. H., Bangsberg, D. R. (2006). Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.. JAMA 296: 679-690 [Abstract] [Full Text]  
• (2006). Generic Antiretroviral Therapy Works Well in Haiti. AIDS Clin Care 2006: 2-2 [Full Text]  
• Tonks, A. (2005). What's new in the other general journals. BMJ 331: 1361-1361 [Full Text]  
• (2005). Potent ART Is Effective in Resource-Poor Countries. JWatch Infect. Diseases 2005: 1-1 [Full Text]  
• Kim, J. Y., Gilks, C. (2005). Scaling up treatment--why we can't wait.. NEJM 353: 2392-2394 [Full Text]